drugset
drugset / Trial / NCT00491699

Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer

NCT00491699 ↗

Phase 1 Terminated 2 enrolled Symphony Evolution, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safest dose of XL999 and how well subjects with Non-Small-Cell Lung Cancer tolerate XL999. XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Timeline

Start
2007-08
Primary completion
2008-01
Completion
2008-05

Outcome

Outcome not reported

Stopped: “The study was stopped due to safety concerns”

Drugs

EvaluationDrugModalityDoseRoute
Subject XL999 Small molecule 0.4 mg/kg Intravenous
Subject XL999 Small molecule 1.6 mg/kg Intravenous

Indications

non-small cell lung carcinoma